The Medical Device Business Journal — Medical Device News & Articles | MassDevice
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
The Food & Drug Administration warned AngioDynamics Inc. (NSDQ:ANGO) for some allegedly over-zealous marketing of its NanoKnife system.
The FDA accused the Latham, N.Y.-based company of making statements on its website promoting the use of the device beyond its approved indications.
Neogen profits jump 33 percent
Neogen Corp. (NSDQ:NEOG) posted profits of $6.1 million, or 26 cents per diluted share, on sales of $43.9 million during the three months ended Nov. 30. That compares with profits of $4.6 million, or 20 cents per diluted share, on sales of $35.3 million during the same period last year.
The safety of AngioDynamics Inc.’s (NSDQ:ANGO) NanoKnife cancer-treatment device is being questioned by surgeons.
The NanoKnife technology, which was developed at the University of California, Berkeley, and licensed to AngioDynamics acquisition Oncobionics, was given FDA 510(k) clearance in 2008 for the treatment of heart ailments. Although it’s legal for physicians to use the device to treat other conditions, some doctors are questioning the risks associated with using the NanoKnife to treat cancer.
Guide Flow LLC filed a lawsuit against six other firms, accusing them of infringing its patent for a "Catheter Guidewire and Flushing Apparatus and Method of Insertion."
The Newport Beach, Calif.-based firm accused C.R. Bard Inc. (NYSE:BCR), AngioDynamics Inc. (NSDQ:ANGO), Becton, Dickinson & Co. (NYSE:BDX), Medical Components Inc., Navilyst Medical Inc. and Smiths Medical ASD Inc. of violating the patent in a suit filed in the U.S. District Court for Utah.
